 Scott Kono
Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 9 | 2022 | 610 | 0.740 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2013 | 968 | 0.610 |
Why?
| | Head and Neck Neoplasms | 7 | 2014 | 471 | 0.550 |
Why?
| | Lung Neoplasms | 7 | 2022 | 2220 | 0.530 |
Why?
| | Receptors, Fibroblast Growth Factor | 2 | 2011 | 63 | 0.440 |
Why?
| | ErbB Receptors | 5 | 2013 | 569 | 0.350 |
Why?
| | Lymph Node Excision | 1 | 2009 | 158 | 0.320 |
Why?
| | Lymphatic Metastasis | 1 | 2009 | 307 | 0.320 |
Why?
| | Empyema, Pleural | 1 | 2007 | 11 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1390 | 0.270 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 671 | 0.250 |
Why?
| | Quinazolines | 2 | 2013 | 245 | 0.200 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2021 | 25 | 0.200 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 1974 | 0.200 |
Why?
| | Pyrazoles | 2 | 2013 | 363 | 0.180 |
Why?
| | Sulfonamides | 2 | 2013 | 445 | 0.180 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 233 | 0.170 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2011 | 229 | 0.170 |
Why?
| | Sirolimus | 2 | 2014 | 195 | 0.140 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1223 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2013 | 812 | 0.130 |
Why?
| | Multi-Institutional Systems | 1 | 2014 | 8 | 0.130 |
Why?
| | SEER Program | 2 | 2013 | 205 | 0.120 |
Why?
| | Social Class | 1 | 2015 | 218 | 0.120 |
Why?
| | Carboplatin | 1 | 2014 | 142 | 0.120 |
Why?
| | Neoplasm Metastasis | 2 | 2014 | 544 | 0.120 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2013 | 19 | 0.110 |
Why?
| | Chemoprevention | 1 | 2013 | 89 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2013 | 71 | 0.110 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 72 | 0.110 |
Why?
| | Maintenance Chemotherapy | 1 | 2012 | 23 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2015 | 278 | 0.110 |
Why?
| | Middle Aged | 12 | 2015 | 27617 | 0.110 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2012 | 18 | 0.100 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2012 | 51 | 0.100 |
Why?
| | Carcinoma, Large Cell | 1 | 2011 | 14 | 0.100 |
Why?
| | Autocrine Communication | 1 | 2011 | 42 | 0.100 |
Why?
| | Gene Rearrangement | 1 | 2011 | 141 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 667 | 0.090 |
Why?
| | Signal Transduction | 3 | 2013 | 4709 | 0.090 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 265 | 0.080 |
Why?
| | Biomedical Research | 1 | 2014 | 612 | 0.080 |
Why?
| | Humans | 19 | 2022 | 118974 | 0.080 |
Why?
| | Radiotherapy | 1 | 2009 | 187 | 0.080 |
Why?
| | Genetic Testing | 1 | 2010 | 389 | 0.080 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2007 | 41 | 0.070 |
Why?
| | Pleural Effusion | 1 | 2007 | 47 | 0.070 |
Why?
| | Biomarkers, Tumor | 2 | 2013 | 1059 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1166 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 811 | 0.060 |
Why?
| | Radiography | 1 | 2007 | 861 | 0.060 |
Why?
| | Survival Rate | 3 | 2013 | 1720 | 0.060 |
Why?
| | Male | 11 | 2015 | 57801 | 0.060 |
Why?
| | Everolimus | 2 | 2014 | 64 | 0.060 |
Why?
| | Celecoxib | 2 | 2013 | 38 | 0.060 |
Why?
| | Erlotinib Hydrochloride | 2 | 2013 | 66 | 0.060 |
Why?
| | Incidence | 3 | 2015 | 2424 | 0.060 |
Why?
| | Aged | 7 | 2014 | 19657 | 0.050 |
Why?
| | Female | 10 | 2015 | 61565 | 0.050 |
Why?
| | Oxazepines | 1 | 2022 | 4 | 0.050 |
Why?
| | Filgrastim | 1 | 2021 | 10 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2022 | 43 | 0.050 |
Why?
| | United States | 4 | 2022 | 12555 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 80 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2013 | 6561 | 0.050 |
Why?
| | Infliximab | 1 | 2021 | 94 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 175 | 0.050 |
Why?
| | Imidazoles | 1 | 2022 | 232 | 0.050 |
Why?
| | Prognosis | 3 | 2013 | 3443 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 341 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2011 | 310 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1419 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 1510 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2012 | 9342 | 0.040 |
Why?
| | Adult | 6 | 2014 | 31512 | 0.040 |
Why?
| | Michigan | 1 | 2015 | 95 | 0.030 |
Why?
| | Demography | 1 | 2015 | 274 | 0.030 |
Why?
| | Health Maintenance Organizations | 1 | 2014 | 96 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2014 | 185 | 0.030 |
Why?
| | Cetuximab | 1 | 2014 | 99 | 0.030 |
Why?
| | Ethmoid Sinus | 1 | 2013 | 8 | 0.030 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2013 | 8 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2013 | 4596 | 0.030 |
Why?
| | Taxoids | 1 | 2013 | 98 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 195 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 649 | 0.030 |
Why?
| | Submandibular Gland Neoplasms | 1 | 2012 | 1 | 0.030 |
Why?
| | Survival Analysis | 1 | 2015 | 1267 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 736 | 0.030 |
Why?
| | Parotid Neoplasms | 1 | 2012 | 16 | 0.030 |
Why?
| | Salivary Gland Neoplasms | 1 | 2012 | 32 | 0.030 |
Why?
| | Recurrence | 1 | 2014 | 975 | 0.030 |
Why?
| | Pemetrexed | 1 | 2011 | 27 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2011 | 41 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 663 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 874 | 0.020 |
Why?
| | Glutamates | 1 | 2011 | 60 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 91 | 0.020 |
Why?
| | Guanine | 1 | 2011 | 75 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 842 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2011 | 154 | 0.020 |
Why?
| | ras Proteins | 1 | 2011 | 141 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 369 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3457 | 0.020 |
Why?
| | Cell Cycle | 1 | 2013 | 550 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1194 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 237 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2010 | 151 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 522 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1474 | 0.020 |
Why?
| | Qualitative Research | 1 | 2013 | 953 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 896 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1012 | 0.020 |
Why?
| | Registries | 1 | 2015 | 1810 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 407 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1691 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 618 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2015 | 12978 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2490 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2275 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 2851 | 0.020 |
Why?
| | Apoptosis | 1 | 2013 | 2484 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 9000 | 0.010 |
Why?
| | Quality of Life | 1 | 2012 | 2366 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 10793 | 0.010 |
Why?
| | Mice | 1 | 2013 | 15520 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 18480 | 0.010 |
Why?
| | Child | 1 | 2012 | 19129 | 0.010 |
Why?
| | Animals | 1 | 2013 | 33381 | 0.010 |
Why?
|
|
Kono's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|